RANBAXY

Members of the Exchange are hereby informed that the trading in equity shares of Ranbaxy Laboratories Limited shall be suspended w.e.f. April 06, 2015 (i.e. closing hours of trading on April 1, 2015) on account of Scheme of Amalgamation with Sun Pharmaceuticals Industries Limited.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy loses drug pleas in US". The Company has clarified that "Previously Company has informed the Exchange on November 21, 2014 that the Company had filed a complaint against the US FDA in D.C. Federal Court and in the first instance asking the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided, which was denied. Following that determination, the Court ordered the parties in the suit to prepare and file legal briefs addressi

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy loses drug pleas in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "EU bans imports from Ranbaxy Unit". The Company has clarified that "The European Medical Agency (EMA) has been referred to as European Authorities in our statement. Further, as informed earlier the Company had decided to stop manufacturing cephalosporin injectables at Dewas much before the inspections by EMA in June, 2014".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased wi

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased wi

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "EU bans imports from Ranbaxy Unit". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Germany bans Ranbaxy drug". The Company has clarified that "The news item is misleading and we wish to clarify as follows in order to place it in the right perspective. The development pertains to only the Company s cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalospo

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Germany bans Ranbaxy drug". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "CCI wants changes to Sun-Ranbaxy deal". The Company has clarified that "we are in communication with the Competition Commission of India (CCI) on specific products and as of now have not received any final order from the CCI regarding divestment of the products".

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "CCI wants changes to Sun-Ranbaxy deal". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information t

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to news item dated November 27, 2014, captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard the Company has clarified that the news item has primarily quoted clarification issued by the Company on November 21, 2014 in response to the query from NSE. The parties to the suit have filed the Schedule for filing additional legal briefs before the US Court. There is nothing further to provide clarification in the matter.

The Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of an

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy fails to block rivals in generic fight". The Company has clarified that " as the Company has earlier informed to the Stock Exchanges that the Company has filed a complaint against the US FDA in D.C. Federal Court and has also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided. The Court has not granted Temporary Restraining Order to block FDA approval for other ANDAs for generic version of Nexium and Valganci

The Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy fails to block rivals in generic fight". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any informati

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Sun, Ranbaxy may be asked to sell some business for CCI approval to merger". The Company has clarified that "The news article suggests that the Competition Commission of India (CCI) may ask the parties to the merger to sell parts of their businesses as a pre-condition to approve the merger. Further, we wish to clarify that as on date we have not received any such communication from the CCI to divest any part of the business(s). The parties have made certain submissions to the CCI on w

The Exchange had sought clarifiation from Ranbaxy Laboratories Limited with respect to a news item captioned "Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor". The Company has clarified that "The Company had in 2008 entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor). This development was communicated to the stock exchanges by the Company vide press release dated June 18, 2008. The lawsuit referred to in the above-referred article was one of the several similar cases filed against the Company and Pfizer Inc

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy faces Rs 242 cr fine in US for violations at Toansa". The Company has clarified that "The Company is not aware of any demand for fine for violation of the type referred to in the news item. The Company, however, is in discussion with authorities in the US for certain other matters, for which the Company believes, it has made adequate provision in its financial statements declared for the quarter ended till June 30, 2014".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Sun-Ranbaxy deal hits hurdle". The Company has clarified that "The Company has neither received any Notice nor appeared/represented before the Hon'ble High Court in regard to aforesaid Court case. Further, we have also not been served the Order of the Hon'ble Court. The subject matter is sub-judice and it would not be appropriate for us to comment on this subject".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy in tie-up to source raw material for Diovan". The Company has clarified that "Company do not disclose individual business transactions as a part of normal course of business, Ranbaxy, as part of its strategy, evaluates alternate viable sourcing of materials from time to time and takes decisions based on the best value that can be derived in the interest of the Company".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "USFDA probes Ranbaxy units - API mftg unit in Toansa". The Company has clarified that "On Saturday, January 11, 2013, Ranbaxy received the form 483 with certain observations as a result of the recent US FDA inspection at its API plant at Toansa, Punjab, India. The Company is assessing the observations, and will respond to the US FDA in accordance with the agency s procedure to resolve the concerns at the earliest. Ranbaxy continues to improve its systems and processes, and remains ful

Ranbaxy Laboratories Limited has submitted to the Exchange, the clarification on news item titled "Pharma CEO Kin stocking up on Ranbaxy Shares" which appeared in Economic Times dated December 12, 2013. In this regard, the Company has responded as under : 1. Since the identity of the CEO and his relative has not been disclosed in the aforesaid news item, therefore the Company are unable to provide any information/disclosure about the purchase of shares by the said person in the Company. 2. Daiichi Sankyo Company, Limited (Promoters of the Company) have confirmed that they have no intention

Ranbaxy Laboratories Limited has informed the Exchange that: "In response to media reports pointing to USFDA website that Ranbaxy has received an Import Alert for its Mohali facility in India, we would like to inform you that the Company has so far not received any communication from the USFDA on this subject. We are seeking information from the USFDA in this regard."

Ranbaxy Laboratories Ltd has informed the Exchange with reference to the news report " Star Ledger Report of July 16 on 'Congress Probe on FDA' " that: "We are not aware of any Congressional Committee inquiry and have not received any communication in this regard. Ranbaxy is a highly regarded Company that has always believed in upholding the highest standards of quality. All our plants are CGMP compliant and produce medicines that meet global norms. During the past 3 years, the FDA has gathered over 200 random samples of various products marketed by the company in the US. These products have b

News Verification : The media had reports that the US department of justice has levelled adulteration charges against the company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "We wish to inform you that, 1) The Government of the United States of America ("the Government") has filed a Motion before the US District Court in the District of Maryland (

News Verification : The media had reports that Ranbaxy Laboratories Ltd may shortly announce a bonus issue. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "The news item stating that the Company may shortly announce a bonus issue is speculative and incorrect."

News Verification : The media had reports that Ranbaxy Laboratories Ltd is likely to pick up stake in a mid-sized Indian drug company for Rs. 20 crores. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated,"As a part of our overall business strategy, we do evaluate various growth opportunities (including possible alliances, investments and acquisition opport

News Verification : The media had reports that Ranbaxy Laboratories Ltd is likely to hive off its research and development (R&D) division into a separate company.. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "The aforesaid news item does not reflect the true simulation. Our R&D is a core inhouse activity of the company. In the case of special proje

Clarification of News : The press had reports that Ranbaxy Laboratories Limited is in advanced stages of acquiring a south-based domestic pharma firm. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "As part of our overall strategy for growth and expansion, we do evaluate various opportunities from time to time. However, as far as the above news item i

Ranbaxy Laboratories Ltd has informed the Exchange that with reference to the news item titled 'Ranbaxy in talks to buy stake in Ind-Swift', appearing in Economic Times of June 10, 2005 the Company has informed that: 1)The news item that Ranbaxy is in talk to buy into Ind-Swift is baseless and without any substance and does not deserve any comment. 2) In regard to acquisition of 18 products from Spanish pharmaceutical company EFARMES, S.A., the company issued a press release on June 09, 2005. 3) In regard to the court case relating to Lipitor, the news of an out of court settlement with Pfizer

Ranbaxy Laboratories Ltd has informed the Exchange that with reference to the News Item appearing in the Economic Times dated March 11, 2005 titled "Promoters increase stake in Ranbaxy Labs", the Company has clarified that the aforesaid news item has wrongly mentioned the promoters stake in the company as 25.59%.The aggregate equity holding of the promoters in the company per disclosure made by the company to the stock exchanges on March 09,2005 was 33.93% of the total share capital of the company.

Ranbaxy Laboratories Ltd has informed the Exchange that the following is with reference to the news item which appeared in Bloomberg/Hindu Business Line dated November 15/16, 2004. The news relates to a matter which emanated in June 2004 and is not a new development. Ranbaxy (UK) Limited (RUKL), along with four other pharmaceutical companies in UK, have been served a notice of claim by the National Health Service, UK, over the alleged anti-competitive behaviour, with respect to the generic drug, Ranitidine. The Company has stated that the company is not aware of any wrong-doing and will contin